Search

Your search keyword '"Borrelli F"' showing total 636 results
Start Over Author "Borrelli F"
636 results on '"Borrelli F"'

101. ARS Component B: structural characterization, tissue expression and regulation of the gene and protein (SLURP-1) associated with Mal de Meleda

Author

Mastrangeli, R., Donini, S., Kelton, C. A., C. M., He, Bressan, A., Milazzo, F., Ciolli, V., Borrelli, F., Martelli, F., Biffoni, M., Serlupi Crescenzi, O., Serani, S., Micangeli, E., El Tayar, N., Vaccaro, Rosa, Renda, Tindaro Giuseppe, Lisciani, R., Rossi, M., and Papoian, R.

Subjects
Keratinocytes, mal de meleda, Mice, Inbred BALB C, hyperkeratosis, Molecular Structure, Reverse Transcriptase Polymerase Chain Reaction, slurp-1, Molecular Sequence Data, ars component b, keratinocytes, Immunohistochemistry, Urokinase-Type Plasminogen Activator, Mice, Keratoderma, Palmoplantar, Animals, Antigens, Ly, Humans, Amino Acid Sequence, RNA, Messenger, Cells, Cultured
Abstract

The ARS Component B gene (EMBL ID: HSARS81S, AC: X99977) encodes a 9 kD non-glycosylated polypeptide (also known as SLURP-1, SwissProt/TrEMBL: P55000), a soluble member of the human Ly6/uPAR superfamily. ARS Component B gene mutations have been implicated in Mal de Meleda. In this study we show by immunohistochemistry that SLURP-1 (secreted Ly-6/uPAR related protein, the protein product of the ARS Component B gene) is localized to human skin, exocervix, gums, stomach and esophagus. In the epidermis, keratinocytes underlying the stratum corneum are highly positive for SLURP1 immunostaining and cultured keratinocytes secrete the expected 9 kD protein. Circulating SLURP1 is detected in human plasma and urine. In the mouse, expression is evident in skin, eye, whole lung, trachea, esophagus and stomach. Human ARS Component B mRNA expression is regulated by retinoic acid, epidermal growth factor and interferon-gamma. The tissue localization and the association with Mal de Meleda suggest that ARS Component B and its protein product SLURP1 are implicated in maintaining the physiological and structural integrity of the keratinocyte layers of the skin.

Published
2004

103. SEMEIOTICA MEDICA DELL'ABUSO SESSUALE NEI BAMBINI PREPUBERI: REQUISITI E RACCOMANDAZIONI

Author

Aprile, Anna, Balboni, R., Baldini, G., Bellora, M. G., Baronciani, D., Borrelli, F., Bova, M. A., Bruni, M., Cattaneo, C., Certosino, M. R., Fadda, N., Furani, S., Dei, M., DI TOMMASO, M., Gabutti, D., Gentilomo, A., Giolito, M. R., Kusterman, A., Loroni, L., Mazzei, A., Motta, T., Negro, F., Offidani, C., Ragazzon, F., Ruspa, M., and Vero, I. G.

Published
2003

105. Beneficial effects of caffeic acid phenethyl ester in a rat model of vascular injury

Author

Maffia, P., Ianaro, A., Pisano, B., Borrelli, F., Capasso, F., Pinto, Aldo, and Ialenti, A.

Subjects
malondialdehyde, Male, 4-dihydroxycinnamic acid) phenethyl ester, Macrophages, adnexal torsion-detorsion model in rats, NF-kappa B, Electrophoretic Mobility Shift Assay, Phenylethyl Alcohol, malondialdehyde, reduced glutathione, xanthine oxidase, caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester, adnexal torsion-detorsion model in rats, caffeic acid (3, Actins, Rats, Isoenzymes, Caffeic Acids, Cyclooxygenase 2, Prostaglandin-Endoperoxide Synthases, Depression, Chemical, Papers, Animals, reduced glutathione, Angioplasty, Balloon, Coronary, Rats, Wistar, Carotid Artery Injuries, Tunica Intima, xanthine oxidase
Abstract

1. The aim of this study was to evaluate whether caffeic acid phenethyl ester (CAPE), an active component of propolis, was able to reduce neointimal formation in a model of endothelial injury of rat carotid artery (balloon angioplasty). Furthermore, we investigated the relationship between neointima formation and nuclear factor-kappaB (NF-kappaB) activation and we correlated NF-kappaB activation to the expression of inducible isoform of cyclo-oxygenase (COX-2) in injured carotids. 2. In control group a significant proliferation of neointima was observed 14 days after balloon angioplasty, which was correlated to an increase of NF-kappaB/DNA binding activity as well as p50/p65 nuclear levels compared to those observed in the carotids from sham-operated rats. Furthermore, NF-kappaB activation was correlated to increased COX-2, but not beta-actin, protein expression. 3. Treatment of rats for 14 days with CAPE (3, 10, 30 mg x kg(-1)) caused a significant inhibition of all the parameters assayed, except beta-actin protein expression. 4. These results indicate that treatment with CAPE may lead to a reduction of neointima formation by inhibiting NF-kappaB activation and suggest that this agent may have therapeutic relevance for the prevention of human restenosis.

Published
2002

108. SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience

Author

Biagio Pinchera, Lorenzo Spirito, Lucia Ferreri, Roberto La Rocca, Giuseppe Celentano, Antonio Riccardo Buonomo, Maria Foggia, Riccardo Scotto, Stefano Federico, Ivan Gentile, Rosa Carrano, “Federico II” COVID-19 Team, Amicone Maria, Borrelli Francesco, Buonomo Antonio Riccardo, Cattaneo Letizia, Conte Maria Carmela Domenica, Cotugno Mariarosaria, Di Filippo Giovanni, Foggia Maria, Gallicchio Antonella, Gentile Ivan, Giaccone Agnese, Lanzardo Amedeo, Mercinelli Simona, Minervini Fulvio, Piccione Amerigo, Pinchera Biagio, Reynaud Laura, Salemi Fabrizio, Sardanelli Alessia, Schiano Moriello Nicola, Scordino Fabrizio, Scotto Riccardo, Stagnaro Francesca, Tosone Grazia, Viceconte Giulio, Zappulo Emanuela, and Zotta Irene

Subjects
kidney transplant, SARS-CoV-2, COVID-19, transplant, immunosuppression, Medicine (General), R5-920
Abstract

BackgroundThe COVID-19 pandemic has significantly impacted the management of solid organ transplant recipients and on clinical evolution in post-transplantation. Little is known on the impact of SARS-CoV-2 infection in these patients. The severity and lethality of this disease in solid organ transplant patients are higher thanin the general population. This study aims to describe clinical characteristics of SARS-CoV-2 infection in solid organ transplant recipients followed in our center.MethodsIn this observational study, we enrolled all kidney transplant recipientsattending the A.O.U. Federico II of Naples from March 2020 to January 2021. For each patient we evaluated the epidemiological and clinical characteristics as well as outcome.ResultsWe enrolled 369 kidney transplant patients (229, male, 62%). Of these, 51 (13.8%) acquired SARS-CoV-2 infection and 29 showed symptomatic disease. Of the 51 patients with the infection, 48 (94.11%) had at least one comorbidity and such comorbidities did not constitute a risk factor for a more severe disease. Hospitalization was necessary for 7 (13.7%) patients. Of these, 2 required low-flow oxygen supplementation, 3 non-invasive/high flow ventilation and 2 invasive ventilation. Finally, 2 patients died.ConclusionsOur study shows a lower mortality and hospitalization rate compared to figures available in the literature (4% vs. 13–30% and 14% vs. 32–100%, respectively). Furthermore, the comorbidities examined (hypertension, dyslipidemia, and diabetes) did not constitute a risk factor for a more severe disease condition in this patient category. Further studies with larger sample size are necessary to confirm these data.

Published
2022
Full Text
View/download PDF

115. Anti-inflammatory activity of Passiflora incarnata L. in rats

Author

Borrelli, F., Pinto, L., Angelo Izzo, Mascolo, N., Capasso, F., Mercati, V., Toja, E., Autore, G., Borrelli, Francesca, Pinto, L., Izzo, ANGELO ANTONIO, Mascolo, NICOLA DOMENICO C. FERDINANDO, Capasso, Francesco, Mercati, V., Toja, E., and Autore, G.

Subjects
Passiflora incarnata L- inflammation-rat
Published
1996

131. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction

Author

Izzo, A.A., Di Carlo, G., Borrelli, F., and Ernst, E.

Subjects
Cardiovascular agents -- Complications and side effects, Anticoagulants (Medicine) -- Complications and side effects, Medicine, Botanic, Drug interactions, Medicine, Herbal, Health, Drug therapy, Complications and side effects
Abstract

Izzo AA, Di Carlo G, Borrelli F, Ernst E. Int J Cardiol 2005:98:1-14. Use of herbal medicines among patients under cardiovascular pharmacotherapy is widespread. In this paper, we have reviewed [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results